Radiological Imaging of Neuroendocrine Tumors
PDF
Cite
Share
Request
Review
P: 278-284
November 2021

Radiological Imaging of Neuroendocrine Tumors

Nucl Med Semin 2021;7(3):278-284
1. İstanbul Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Radyoloji Anabilim Dalı, İstanbul, Türkiye
No information available.
No information available
PDF
Cite
Share
Request

ABSTRACT

Neuroendocrine tumors are a heterogeneous group of neoplasms with various clinical and imaging findings and there has been significant developments in diagnosis in recent years. On the other hand, a significant number of patients are still diagnosed after metastasis. However, this situation often does not constitute an obstacle for curative treatment. Tumor burden assessment usually requires the use of multiple imaging modalities, including computed tomography, magnetic resonance imaging, ultrasound, and somatostatin receptor-based imaging. Accurate staging is the most important factor in treatment planning. For this reason, accurate imaging is one of the indispensable steps for diagnosis, staging, treatment plan and follow-up. Various imaging techniques have been developed and optimized to accurately assess tumor burden in these patients. Morphological and functional imaging methods, which are basically considered in two classes, developed for this purpose and are often used in combination. In this article, current radiological imaging methods and findings used in the diagnosis of neuroendocrine tumors will be reviewed.

References

1Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 2011;396:273-298.
2Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
3Zheng Z, Chen C, Jiang L, et al. Incidence and risk factors of gastrointestinal neuroendocrine neoplasm metastasis in liver, lung, bone, and brain: A population-based study. Cancer Med 2019;8:7288-7298.
4Sundin A, Vullierme MP, Kaltsas G, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009;90:167-183.
5Lodish MB, Stratakis CA. Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes. Best Pract Res Clin Endocrinol Metab 2010;24:439-449.
6Toumpanakis CG, Caplin ME. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Am J Gastroenterol 2008;103:729-732.
7Waldmann J, Fendrich V, Habbe N, et al. Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value. World J Surg 2009;33:1208-1218.
8Hilal T. Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Ther Adv Med Oncol 201;9:189-199.
9Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics 2006;26:41-58.
10Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer 2013;20:187-196.
11Pape UF, Berndt U, Müller-Nordhorn J, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008;15:1083-1097.
12Pirasteh A, Lovrec P, Bodei L. Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities. Rev Endocr Metab Disord 2021;22:539-552.
13Van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ. Neuroendocrine tumours: The role of imaging for diagnosis and therapy. Nat Rev Endocrinol [Internet] 2014;10:102-114. Available from: http://dx.doi.org/10.1038/nrendo.2013.246
14Low G, Panu A, Millo N, Leen E. Multimodality imaging of neoplastic and nonneoplastic solid lesions of the pancreas. Radiographics 2011;31:993-1015.
15Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol 2013;24:3040-3044.
16Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J Cancer 2012;3:292-302.
17Del Prete M, Di Sarno A, Modica R, et al. Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors. J Endocrinol Invest 2017;40:1373-1380.
18Serra C, Felicani C, Mazzotta E, et al. Contrast-enhanced ultrasound in the differential diagnosis of exocrine versus neuroendocrine pancreatic tumors. Pancreas 2013;42:871-877.
19Sundin A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012;26:803-818.
20Tan EH, Tan CH. Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol 2011;2:28-43.
21Ruf J, Schiefer J, Furth C, et al. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med 2011;52:697-704.
22Park HJ, Kim HJ, Kim KW, et al. Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT. Eur Radiol 2020;30:4772-4782.
23Howe JR, Cardona K, Fraker DL, et al. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas 2017;46:715-731.
24Kamaoui I, De-Luca V, Ficarelli S, Mennesson N, Lombard-Bohas C, Pilleul F. Value of CT enteroclysis in suspected small-bowel carcinoid tumors. AJR Am J Roentgenol 2010;194:629-633.
25Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2016;103:153-171.
26Hope TA, Pampaloni MH, Nakakura E, et al. Simultaneous (68) Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging 2015;40:1432-1440.
27Schreiter NF, Nogami M, Steffen I, et al. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur Radiol 2012;22:458-467.
28Berzaczy D, Giraudo C, Haug AR, et al. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients. Clin Nucl Med 2017;42:669-674.
29d’Assignies G, Fina P, Bruno O, et al. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology 2013;268:390-399.
30Moryoussef F, de Mestier L, Belkebir M, et al. Impact of Liver and Whole-Body Diffusion-Weighted MRI for Neuroendocrine Tumors on Patient Management: A Pilot Study. Neuroendocrinology 2017;104:264-272.
31Lee L, Ito T, Jensen RT. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther 2018;18:837-860.
Article is only available in PDF format. Show PDF
2024 ©️ Galenos Publishing House